Xintela AB Interim Report January – March 2023
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First quarter 2023 for the groupIncome amounted to TSEK 0 (0).Loss before and tax totalled TSEK 15,843 (loss: 16,383).Loss per share* was SEK 0.05 (loss: 0.18). First quarter 2023 for the parent companyIncome amounted to TSEK 0 (0).Loss before […]
Communiqué from the Annual General Meeting of Xintela AB (publ)
Today, Friday 12 May 2023, the Annual General Meeting was held in Xintela AB (publ). The following main decisions were made. The decisions were taken unanimously. Profit allocation and decision on discharge from liabilityThe meeting decided, in accordance with the board’s proposal, that no dividend is to be paid for the financial year 2022 and […]
Xintela AB publishes Annual Report 2022
Xintela AB (publ) announces that the Swedish version of the company’s Annual Report for 2022 is published on the company’s website, www.xintela.se. The English version will be published shortly. Link to the annual report:https://www.xintela.se/en/report-archive Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical […]
Xintela has started last dose level of XSTEM in knee osteoarthritis clinical study
Xintela’s first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis, being conducted in Australia, is testing three different dose levels of the stem cell product XSTEM®. The Safety Review Committee for the clinical study assessed the treatment of the eight patients on the second dose level with XSTEM at the one-month follow-up, concluded the […]
Xintela AB: BioStock Investor Meeting with Xintela
Do not miss Xintela’s presentation at the BioStock Investor Meeting, today March 16 at 10.40 am. The event starts at 10.00 – see the full programme on BioStock’s website or YouTube channel. CEO Evy Lundgren-Åkerlund will present Xintela at the BioStock Investor Meeting (https://www.biostock.se/investormeetingmarch23/), starting at 10.40 am. This is a press release from BioStock – Connecting […]
Xintela completes dosing of XSTEM second dose level in knee osteoarthritis clinical study
Xintela’s first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis, being conducted in Australia, is testing 3 different dose levels of the stem cell product XSTEM®. All patients at the second dose level have now been dosed. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. […]
Xintela Year-end report 2022
Summary of the year-end report. The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Third quarter 2022 for the group Fourth quarter 2022 for the groupIncome amounted to TSEK 0 (0).Loss before and tax totalled TSEK 23,384 (loss: 18,013).Loss per share* was SEK 0.09 (loss: 0.20). Twelve months 2022 for the groupIncome […]
Xintela newsletter December 2022
Dear shareholder, First of all, I want to thank you for your support and engagement during the past year and wish you a very Happy New Year. I also want to take the opportunity to summarize Xintela’s and Targinta’s exciting development in 2022 and draw attention to important achieved and upcoming milestones. It has been […]
Xintela and NorthX Biologics sign collaboration framework agreement
Xintela and NorthX Biologics announce they have signed a collaboration framework agreement to facilitate projects of common interest utilizing their complementary resources and competences in developing and manufacturing Advanced Therapy Medicinal Products (ATMPs). Projects to be initiated under the collaboration framework include product and process development, quality management and expansion capacity for manufacturing ATMPs, among […]
Xintela obtains US patent for stem cell treatment
Xintela announces that the US patent office USPTO has today approved the company’s patent application for treatment of musculoskeletal diseases using Xintela’s stem cell products. The USPTO today issued Xintela’s patent US 11,517,593 covering stem cell treatment of musculoskeletal diseases including osteoarthritis and other degenerative joint diseases as well as treatment of traumatic joint injuries […]
